Bcr-Abl
Bcr-Abl inhibitors are targeted therapies that inhibit the Bcr-Abl fusion protein, which is formed due to the Philadelphia chromosome translocation and is a driver of chronic myeloid leukemia (CML). This protein also influences angiogenesis, contributing to tumor progression. Bcr-Abl inhibitors are crucial in the treatment of CML and are being explored for their potential in inhibiting angiogenesis in various cancers. At CymitQuimica, we provide high-quality Bcr-Abl inhibitors to support your research in cancer biology, angiogenesis, and targeted therapy.
Products of "Bcr-Abl"
Sort by
Asciminib
CAS:Asciminib (ABL001) (ABL001) is a potent and selective Bcr-Abl inhibitor (Kd: 0.5-0.8nM).Formula:C20H18ClF2N5O3Purity:97.93% - 99.45%Color and Shape:SolidMolecular weight:449.84Ref: TM-T5177
1mg63.00€2mg92.00€5mg127.00€10mg187.00€25mg305.00€50mg427.00€100mg630.00€500mg1,320.00€1mL*10mM (DMSO)139.00€Bafetinib
CAS:Bafetinib (INNO-406): Dual Bcr-Abl/Lyn inhibitor; IC50: 5.8/19 nM; ineffective against T315I mutant, less on c-Kit/PDGFR.Formula:C30H31F3N8OPurity:94.16% - 99.68%Color and Shape:SolidMolecular weight:576.62Ref: TM-T6311
1mg37.00€2mg52.00€5mg79.00€10mg103.00€25mg159.00€50mg188.00€100mg350.00€200mg455.00€1mL*10mM (DMSO)90.00€BCR-ABL-IN-9
BCR-ABL-IN-9 (Compound B1) is an inhibitor of BCR-ABL that achieves sustained suppression through the formation of stable covalent bonds with the ABL kinase. It effectively inhibits the activity of ABL kinase (IC50 = 1.2 nM) and possesses anticancer activity.Formula:C22H20N4O3Color and Shape:SolidMolecular weight:388.42
